Analysis:

## (a) Source Analysis

**Yahoo Finance (Simply Wall St) - January 29, 2026:**
High-quality financial analysis platform. Reports UHS last close at ~$200.13, down 11% (1-month) and 8% (3-month). Fair value estimate $250.41 implies 20.1% undervaluation. **Factual data**: Price levels, returns. **Opinions**: Valuation model ($250.41 fair value) is proprietary methodology; strategic expansion views are analyst commentary without named attribution - treat cautiously.

**MarketBeat (Summit Global) - February 1, 2026:**
Reliable institutional holdings tracker. Reports UHS opened at $201.17 on Friday (Jan 31, 2026). Key data: Market cap $12.57B, P/E 9.56, 50-day MA $219.56, 200-day MA $203.01. **Factual data**: Price, moving averages, institutional holdings (86.05%). **Opinions**: Analyst ratings from named firms (Wells Fargo $235 target "equal weight" Jan 7; Guggenheim $274 "buy" Dec 2; Raymond James $270 "outperform" Nov 3). Consensus: "Hold" with $234.13 average target. These are identifiable expert opinions - reliable for sentiment.

**MarketBeat (Teacher Retirement) - January 27, 2026:**
Similar quality source. Reports opening at $206.02 on Tuesday (Jan 21, 2026 approximately). Q3 earnings beat: $5.69 EPS vs $4.66 estimate. **Factual data**: Earnings results, institutional activity. **Opinions**: Same analyst consensus as above source ($234.13 target, "Hold" rating) from identifiable firms.

**Fierce Healthcare - October 30, 2025:**
Industry-focused news outlet. Reports UHS Q3 2025 saw 9.8% same-store revenue jump, with half from Medicaid supplemental payments. Notes "One Big Beautiful Bill Act" will clip supplemental payments in future years. **Factual data**: Q3 revenue metrics, stock trading higher post-earnings. **Opinions**: Executive quotes on ACA impact (Kevin Hammons, Michael Marks, Dr. Saum Sutaria) - identifiable sources discussing policy uncertainty.

**Stock Titan - October 8, 2025:**
Corporate announcement aggregator. Notes Q3 earnings announcement date (Oct 27, 2025) and 1.75% stock decline on announcement day. **Factual**: Scheduled event date. No forward-looking substance.

**AskNews Articles - February 1-2, 2026:**
Multiple recent sources confirming:
- Summit Global reduced stake by 74.5% (Defense World, Feb 1)
- AlphaQuest increased stake by 88.7% (Defense World, Feb 1)
- Stock opened at $201.17 on Friday Jan 31 (multiple sources)
- Insider Warren Nimetz sold 3,817 shares at $223.30 in November, reducing position 31.04%
- 86.05% institutional ownership confirmed
- Consensus "Hold" rating, $234.13 target confirmed

**Historical articles (Nov-Dec 2025):**
CEO extension through 2029 announced Dec 31, 2025 (SentimentTrading). Stock reached 52-week high of $227.27 in early November after Raymond James upgrade to "Outperform" $270 target. Q3 results beat expectations significantly.

**Quality Assessment**: Recent sources (Jan 27-Feb 2, 2026) are highly relevant and factual. Analyst opinions are from identifiable major firms (Wells Fargo, Guggenheim, Raymond James, etc.) - reliable for sentiment. Institutional and insider transaction data is SEC-verified.

## (b) Evidence Analysis

**Strong Evidence:**
- **Current price anchoring**: Multiple independent sources confirm UHS trading around $200-206 range as of Jan 27-Feb 2, 2026. Stock opened at $201.17 on Jan 31 (MarketBeat, AskNews). This is ~$201-203 baseline for Feb 2 close.
- **Technical positioning**: Stock trading below both 50-day MA ($219.56) and near 200-day MA ($203.01). Recent decline from November high of $227.27 to current ~$201 represents 11.5% pullback.
- **Analyst consensus**: Multiple named sources (Wells Fargo, Guggenheim, Raymond James, RBC, UBS) with average target $234.13, but recent Wells Fargo downgrade to "Equal Weight" $235 (Jan 7, 2026) signals caution.

**Moderate Evidence:**
- **Insider selling pattern**: Director Nimetz sold 31% of position in November at $223.30. Summit Global reduced 74.5% stake in Q3. No insider purchases reported. This suggests insiders taking profits at higher levels.
- **Momentum shift**: Stock down 11% over 1 month (per Simply Wall St Jan 29), indicating negative near-term momentum into February.
- **Valuation support**: P/E of 9.56 vs historical norms suggests undervaluation, but this is long-term factor unlikely to drive 10-day movement.

**Weak Evidence:**
- **Macro calendar**: NFP (Feb 6) and CPI (Feb 11) could create volatility but direction unpredictable.
- **No catalyst**: No earnings or corporate events Feb 2-14 means no obvious positive driver.
- **Policy uncertainty**: Medicaid payment clawback risk (Fierce Healthcare) is medium-term concern, not 10-day factor.

## (c) Timeframe Analysis

**Timeframe**: 10 trading days (Feb 2 close to Feb 14 close = 8-9 actual trading days accounting for weekends).

**Characteristics of this timeframe:**
- Too short for fundamental valuation to matter significantly
- Technical factors and momentum dominate
- News flow and macro events can cause volatility but direction is random
- Typical 10-day stock movements approximate random walk around slight trend

**If timeframe halved (5 days)**: Would increase randomness further, probability would converge closer to 50% as momentum and technical factors have less time to develop.

**If timeframe doubled (20 days)**: Would allow more time for mean reversion to 50-day MA ($219.56), increasing probability of upward movement. Analyst targets would become slightly more relevant. Would shift probability toward 52-55% range.

**Current 10-day assessment**: Stock at $201-203 is 8.4% below 50-day MA and just at/slightly below 200-day MA. Recent negative momentum (down 11% in 1 month) suggests continued near-term weakness more likely than reversal in just 10 days.

## (d) Justification

**Starting from outside view base rate of 47%** (established for general 10-day stock movements with slight negative bias).

**Factors shifting probability DOWN from 47%:**

1. **Recent negative momentum (-11% over 1 month)**: Stock in downtrend entering February. Momentum tends to persist over 1-2 week periods. **Shift: -4%**

2. **Technical breakdown below 50-day MA**: Stock at $201 vs 50-day MA of $219.56 (8.4% below). Technicians often view this as continued weakness signal. **Shift: -3%**

3. **Insider selling concentration**: Nimetz sold at $223, Summit Global exited 74.5% at higher levels. Insiders rarely have 10-day timing edge but signals lack of confidence at current levels. **Shift: -2%**

4. **No positive catalyst**: No earnings, no corporate events Feb 2-14. In absence of catalyst, negative momentum likely continues. **Shift: -2%**

**Factors shifting probability UP from 47%:**

1. **Oversold vs 50-day MA**: 8.4% below 50-day MA could trigger technical bounce, though 10 days may be too short. **Shift: +2%**

2. **Analyst targets averaging $234**: Implies 16% upside from ~$201, but this is medium-term view. Some institutional support (AlphaQuest increased 88.7%). **Shift: +1%**

3. **Near 200-day MA support**: Stock at $201 vs 200-day MA $203 suggests potential floor. **Shift: +1%**

**Net adjustment: -7% from base rate of 47% = 40%**

However, I need to reconsider the magnitude of these shifts. The 10-day timeframe is very short, and:
- Recent momentum is clear and strong (11% decline in 1 month)
- Technical position is weak (below 50-day MA)
- No catalyst to reverse trend
- But stock near 200-day MA support could limit further downside

The -7% total shift may be slightly too aggressive. Recent momentum is the strongest signal, but 10-day movements still have substantial randomness. Adjusting to -5% shift seems more calibrated.

**Revised: 47% - 5% = 42%**

## Probability Calibration

Starting from outside view of 47% for general 10-day positive stock movements with slight negative bias, I adjust based on UHS-specific factors:

**Key adjustments:**
- Strong negative momentum (-11% over 1 month entering February): -3%
- Technical weakness (8.4% below 50-day MA): -2%
- No positive catalyst scheduled Feb 2-14: -1%
- Partial offset from 200-day MA support: +1%

**Net adjustment: -5%**

**Final calibrated probability: 42%**

This implies 42 out of 100 times, in similar circumstances (stock in recent downtrend, trading below key moving averages, no catalyst, 10-day timeframe), the stock would close higher at the end period.

The probability reflects that negative momentum tends to persist over 1-2 week periods more often than it reverses, but the 10-day timeframe still contains substantial randomness preventing extreme confidence in either direction.

## Checklist:

1. **Paraphrase**: Will UHS stock close on Feb 14, 2026 be higher than Feb 2, 2026 close? (~10 trading days)

2. **Base rate**: 47% for 10-day positive returns with slight negative bias. Final 42% maintains connection to this base rate with modest UHS-specific adjustments.

3. **Consistency**: "42 out of 100 times, UHS closes higher on Feb 14 vs Feb 2." This aligns with recent downward momentum persisting more often than reversing over 10 days, while acknowledging substantial short-term randomness.

4. **Key evidence**:
   - Stock down 11% over past month, negative momentum entering February (factual - multiple sources)
   - Trading 8.4% below 50-day MA at $201 vs $219.56 (factual - MarketBeat Jan 31)
   - No corporate catalyst Feb 2-14 (factual - no scheduled events)
   - Insider selling pattern (factual - SEC filings, Nimetz -31% Nov 2025)
   - Near 200-day MA support at $203 (factual - MarketBeat)

5. **Blind spot**: Unexpected positive macro surprise (strong NFP/CPI data suggesting soft landing) could trigger broad market rally lifting UHS despite lack of company-specific catalyst. This could shift probability to 48-50% range. Alternatively, healthcare sector-specific positive policy news could reverse momentum.

6. **Status quo**: Over 10 days, status quo is continuation of recent trend (downward). Stock has declined 11% over past month and broken below 50-day MA. Absent catalyst, momentum persistence is more likely than reversal. Current 42% appropriately reflects slight bias toward status quo (continued weakness) while maintaining substantial uncertainty given short timeframe.

Probability: 42%